With more drugs in clinical trials than any other country, Chinese drugmakers are now shifting focus to the high-risk, high-reward field of creating truly original medicines to move beyond an era of imitation and intense competition
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
As Chinese pharmaceutical companies make waves with a series of major
‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.
The country’s drug evaluation agency registered a jump in new drug and clinical trial applications, signaling a robust pivot…
Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms,…
Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink
